Test Directory

Monitoring antiresorptive therapies (eg, bisphosphonates and hormone replacement therapy) in postmenopausal women treated for osteoporosis and individuals diagnosed with osteopenia.

An adjunct in the diagnosis of medical conditions associated with increased bone turnover.

Specimen Type: Serum

Preferred Collection Container: Red Top, Plain

Alternate Collection Container: Gold Top, Serum Separator

Desired Specimen Volume: 1 mL

1. Collect specimen prior to 10 a.m.
2. Collect a red top, plain tube via venipuncture.

1. Separate serum from cells.
2. Transfer 1 mL of serum to a clear aliquot tube (screw cap) and freeze.

Fasting: 12 hours, required

Transport to the laboratory frozen.

• Gross hemolysis
• Gross icterus

See patient report.

Reduced kidney function may lead to reduced urinary excretion of beta-C-terminal telopeptide (CTx) and a consequent increase in the apparent serum beta-CTx concentration.

In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies [HAMA] or heterophile antibodies), which may cause interference in some immunoassays. The presence of antibodies to streptavidin or ruthenium can rarely occur and may interfere in this assay. Caution should be used in interpretation of results, and the laboratory should be alerted if the result does not correlate with the clinical presentation.

Serum biotin concentrations up to 1200 ng/mL do not interfere with this assay. Concentrations up to 1200 ng/mL may be present in specimens collected from patients taking extremely high doses of biotin up to 300 mg per day. In a study among 54 healthy volunteers, supplementation with 20 mg/day biotin resulted in a maximum serum biotin concentration of 355 ng/mL 1-hour postdose.

• B-CTx
• Beta CrossLaps
• Beta-CTx
• C-Telopeptide
• C-terminal collagen crosslinks
• Carboxy terminal collagen crosslinks
• CTx